MGMT and glioma: Following this finding, they concluded that CpG combinations with four or more consecutive CpGs within CpGs 72–82, including the combinations of CpGs 76–79 and CpGs 74–78 used in commercial kits, are equally effective at predicting MGMT mRNA expression and the survival of TMZ treated glioma patients.